ArticleJournal of experimental orthopaedics2026
Dual-antibiotic bone cement (gentamicin + vancomycin) in preventing and treating infections during revision knee arthroplasty in high-risk patients.
Article in Journal of experimental orthopaedics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antibiotic-Loaded PLA Composites for Local Prevention of Implant-Associated Infections: Comparative Evaluation Against Reference Strains and Clinical Isolates.Antibiotics (Basel, Switzerland) · 2026Article
- Dual-antibiotic bone cement (gentamicin + vancomycin) in preventing and treating infections during revision knee arthroplasty in high-risk patients.Journal of experimental orthopaedics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the treatment and preventive effects, as well as the safety, of dual-antibiotic bone cement (DABC; gentamicin + vancomycin) in revision total knee arthroplasty (RTKA) in high-risk patients. Methods: This retrospective observational study included patients who underwent RTKA for septic or aseptic indications with intraoperative application of DABC (Copal G + V, Heraeus-Medical GmbH) at our centre between December 2015 and December 2022. Patients were followed for a minimum of 2 years. Postoperative infection rates were documented, and preoperative patient risk was calculated using the periprosthetic joint infection (PJI) risk calculator. Microbiological profiles and antibiotic resistance patterns of postoperative infections were analysed, and all complications were recorded. Results: A total of 85 patients were included. The overall postoperative infection rate after DABC use was 17.6% (15/85), 95% confidence interval (CI) [11.0%, 27.1%], while the mean preoperative PJI risk percentage was 54.19 ± 16.58%. When stratified by revision indication, infection rates were 21.2% (14/66), 95% CI [13.1%, 32.5%] in septic revisions and 5.3% (1/19), 95% CI [0.9%, 24.6%] in aseptic revisions, with corresponding preoperative PJI risk values of 54.34 ± 16.95% and 53.65 ± 15.62%. Among the 15 patients who developed postoperative infections, the most common organisms were Conclusions: DABC (G + V) demonstrated favourable infection control in septic RTKA and effective infection prevention in aseptic RTKA, with a low complication rate and good overall safety. Level of Evidence: Level III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.